|
1
|
Rendón-Elíasa FG, Hernández-Sánchez M,
Albores-Figueroa R, Montes-Tapia FF and Gómez-Danés LH: Congenital
vascular malformations update. Med Univer. 16:184–198. 2014.
|
|
2
|
Behr GG and Johnson C: Vascular anomalies:
Hemangiomas and beyond-part I, Fast-flow lesions. AJR Am J
Roentgenol. 200:414–422. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Behr GG and Johnson C: Vascular anomalies:
Hemangiomas and beyond-part 2, Slow flow lesions. AJR Am J
Roentgenol. 200:423–436. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
White CL, Olivieri B, Restrepo R, McKeon
B, Karakas SP and Lee EY: Low-flow vascular malformation pitfalls:
From clinical examination to practical imaging evaluation-part 1,
lymphatic malformation mimickers. AJR Am J Roentgenol. 206:940–951.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cox JA, Bartlett E and Lee EI: Vascular
malformations: A review. Semin Plast Surg. 28:58–63.
2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Behravesh S, Yakes W, Gupta N, Naidu S,
Chong BW, Khademhosseini A and Oklu R: Venous malformations:
Clinical diagnosis and treatment. Cardiovasc Diagn Ther. 6:557–569.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zheng W, Aspelund A and Alitalo K:
Lymphangiogenic factors, mechanisms and applications. J Clin
Invest. 124:878–887. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Colbert SD, Seager L, Haider F, Evans BT,
Anand R and Brennan PA: Lymphatic malformations of the head and
neck-current concepts in management. Br J Oral Maxilofac Surg.
51:98–102. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Amodeo I, Colnaghi M, Raffaeli G,
Cavallaro G, Ciralli F, Gangi S, Leva E, Pignataro L, Borzani I,
Pugni L and Mosca F: The use of sirolimus in the treatment of giant
cystic lymphangioma: Four case reports and update of medical
therapy. Medicine (Baltimore). 96(e8871)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hammill AM, Wentzel MS, Gupta A, Nelson S,
Lucky A, Elluru R, Dasgupta R, Azizkhan RG and Adams DM: Sirolimus
for the treatment of complicated vascular anomalies in children.
Clin Med Insights Blood Disord. 57:1018–1024. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mahajan P, Margolin J and Iacobas I:
Kasabach-merritt phenomenon: Classic presentation and management
options. Clin Med Insights Blood Disord.
10(1179545X17699849)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ji Y, Chen S, Yang K, Xia C and Li L:
Kaposiform hemangioendothelioma: Current knowledge and future
perspectives. Orphaneet J Rare Dis. 15(39)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang B and Ma L: Updated classification
and therapy of vascular malformations in pediatric patients.
Pediatr Invest. 2:119–123. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Raphael MF, Breur JM, Vlasveld FA, Elbert
NJ, Liem YT, Kon M, Breugem CC and Pasmans SG: Treatment of
infantile hemangiomas: Therapeutic options in regard to side
effects and adverse events-a review of the literature. Expert Opin
Drug Saf. 15:199–214. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Droitcourt C, Kerbrat S, Rault C, Botrel
MA, Happe A, Garlantezec R, Guillot B, Schleich JM, Oger E and
Dupuy A: Safety of oral propranolol for infantile hemangioma.
Pediatrics. 141(e20173783)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Léauté-Labrèze C, Hoeger P,
Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ,
Caceres H, Lopez Gutierrez JC, Ballona R, et al: A randomized,
controlled trial of oral propranolol in infantile hemangioma. N
Engl J Med. 372:735–746. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Triana P, Miguel M, Díaz M, Cabrera M and
López Gutiérrez JC: Oral sirolimus: An option in the management of
neonates with life-threatening upper airway lymphatic
malformations. Lymphat Res Biol. 17:504–511. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang Z, Yao W, Sun H, Dong K, Ma Y, Chen
L, Zheng S and Li K: Sirolimus therapy for kaposiform
hemangioendothelioma with long-term follow-up. J Dermatol.
46:956–961. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Adams DM, Trenor CC III, Hammill AM, Vinks
AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell
LM, Brookbank C, et al: Efficacy and safety of sirolimus in the
treatment of complicated vascular anomalies. Pediatrics.
137(e20153257)2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Freixo C, Ferreira V, Martins J, Almeida
R, Caldeira D, Rosa M, Costa J and Ferreira J: Efficacy and safety
of sirolimus in the treatment of vascular anomalies: A systematic
review. J Vasc Surg. 71:318–327. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sandbank S, Molho-Pessach V, Farkas A,
Barzilai A and Greenberger S: Oral and topical sirolimus for
vascular anomalies: A multicentre study and review. Acta Derm
Venereol. 99:990–996. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Honnorat M, Viremouneix L, Ayari S,
Guibaud L, Coste K, Claris O and Butin M: Early adjuvant medication
with the mTOR inhibitor sirolimus in a preterm neonate with
compressive cystic lymphatic malformation. Front Pediatr.
8(418)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Cirstoveanu C, Bizubac M, Mustea C,
Barascu I, Manolache S, Nine L, Istrate-Barzan A, Spataru R and
Marcu V: Combined antiproliferative therapy with rapamycin and
propranolol for giant congenital lymphangioma. Chest.
157(A317)2020.
|
|
24
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4(51)2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Laplante M and Sabatini DM: mTOR signaling
at a glance. J Cell Sci. 122:3589–3594. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Greenberger S, Yuan S, Walsh LA, Boscolo
E, Kang KT, Matthews B, Mulliken JB and Bischoff J: Rapamycin
suppresses self-renewal and vasculogenic potential of stem cells
isolated from infantile hemangioma. J Invest Dermatol.
131:2467–2476. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lin Z, Wang L, Huang G, Wang W and Lin H:
Propranolol inhibits the activity of PI3K, AKT, and HIF-1α in
infantile hemangiomas. Pediatr Surg Int. 34:1233–1238.
2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Pan WK, Li P, Guo ZT, Huang Q and Gao Y:
Propranolol induces regression of hemangioma cells via the
down-regulation of the PI3K/Akt/eNOS/VEGF pathway. Pediatr Blood
Cancer. 62:1414–1420. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Mahalati K and Kahan BD: Clinical
pharmacokinetics of sirolimus. Clin Pharmacokinet. 40:573–585.
2001.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chinello M, Di Carlo D, Olivieri F, Balter
R, De Bortoli M, Vitale V, Zaccaron A, Bonetti E, Parisi A and
Cesaro S: Successful management of kaposiform hemangioendothelioma
with long-term sirolimus treatment: A case report and review of the
literature. Mediterr J Hematol Infect Dis.
10(e2018043)2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Mukhopadhyay S, Frias MA, Chatterjee A,
Yellen P and Foster DA: The enigma of rapamycin dosage. Mol Cancer
Ther. 15:347–353. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Alaqeel AM, Alfurayh NA, Alhedyani AA and
Alajlan SM: Sirolimus for treatment of kaposiform
hemangioendothelioma associated with Kasabach-Merritt phenomenon.
JAAD Case Rep. 2:457–461. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Warren D, Diaz L and Levy M: Diffuse
hepatic hemangiomas successfully treated using sirolimus and
high-dose propranolol. Pediatr Dermatol. 34:e286–e287.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Drolet BA, Trenor CC III, Brandão LR, Chiu
YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan
B, et al: Consensus-derived practice standards plan for complicated
Kaposiform hemangioendothelioma. J Pediatr. 163:285–291.
2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ji Y, Chen S, Xia C, Zhou J, Jiang X, Xu
X, Yang K, Zhang X, Kong F, Lu G and Zhang Y: Chronic lymphedema in
patients with kaposiform hemangioendothelioma: Incidence, clinical
features, risk factors and management. Orphanet J Rare Dis.
15(313)2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Konczyk DJ, Goss JA, Maclellan RA and
Greene AK: Association between extremity kaposiform
hemangioendothelioma and lymphedema. Pediatr Dermatol. 35:e92–e93.
2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Morrisett JD, Abdel-Fattah G and Kahan BD:
Sirolimus changes lipid concentrations and lipoprotein metabolism
in kidney transplant recipients. Transplant Proc. 35(3
Suppl):143S–150S. 2003.PubMed/NCBI View Article : Google Scholar
|
